Comparison of the Glycemic Effects of Rosiglitazone and Pioglitazone in Triple Oral Therapy in Type 2 Diabetes

RESEARCH DESIGN AND METHODS - Our diabetes clinic treatment algorithm mandates starting small doses of either a sulfonylurea agent or metformin and increasing the dose every 2 weeks until either a fasting plasma glucose (FPG) concentration of

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2006-06, Vol.29 (6), p.1395-1396
Hauptverfasser:	Tran, Michael T, Navar, Maria D, Davidson, Mayer B
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Blood Glucose - metabolism Clinical trials Comparative studies Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Dosage and administration Drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Male Medical sciences Middle Aged Patients Retrospective Studies Rosiglitazone maleate Thiazolidinediones - administration & dosage Thiazolidinediones - therapeutic use Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	RESEARCH DESIGN AND METHODS - Our diabetes clinic treatment algorithm mandates starting small doses of either a sulfonylurea agent or metformin and increasing the dose every 2 weeks until either a fasting plasma glucose (FPG) concentration of
ISSN:	0149-5992 1935-5548
DOI:	10.2337/dc06-0494